Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$136.06 USD
+1.81 (1.35%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $136.03 -0.03 (-0.02%) 6:54 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Jazz Pharmaceuticals PLC has a market cap of $8.14B, which represents its share price of $134.25 multiplied by its outstanding shares number of 60.66M. As a mid-cap company, JAZZ's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
JAZZ 136.06 +1.81(1.35%)
Will JAZZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Other News for JAZZ
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
First Week of June 2026 Options Trading For Jazz Pharmaceuticals (JAZZ)
JAZZ falls 1.14% on October 16, leaving the technical picture intact
Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
Is JAZZ positioned for a breakout? 20 Day Moving Average Support shows up after climbing 1.49%